Sophie M. Lanzkron, MD, MHS; Jeffrey D. Lebensburger, DO, MSPH; and John J. Strouse, MD, PhD, explore current therapy options for the management of sickle cell disease and discuss the impact of anemia and hemolysis.
Jeffrey D. Lebensburger, DO, MSPH, and John J. Strouse, MD, PhD, comment on the serious complications of anemia and hemolysis caused by sickle cell disease and the impact on pediatric patients vs adults.
Sophie M. Lanzkron, MD, MHS, and Jeffrey D. Lebensburger, DO, MSPH, review the underlying pathophysiology of acute multisystem organ failure and resulting cerebrovascular and neurologic complications associated with sickle cell disease.
Experts in hematology discuss NHLBI guideline recommendations for the screening and monitoring of anemia-related disease manifestations as well as goals of therapy for patients with sickle cell disease.
Expert hematologists comment on the use of crizanlizumab in reducing painful crisis frequency in sickle cell disease and share their experience with the drug in clinical practice.
Drs Sophie M. Lanzkron, Jeffrey D. Lebensburger, and John J. Strouse, share insights on the safety profile and cost of gene therapy for the management of sickle cell disease.